source
- Argenx to acquire Forte Biosciences for $2.2 billion, securing phase-2 vitiligo antibody FB102Argenx announced it will buy Forte Biosciences for $2.2 billion, gaining access to FB102, an anti‑CD122 antibody currently in phase‑2 trials for vitiligo and celiac disease. In a recent phase 1b s…
- Apnimed targets up to $160 million IPO to fund launch of Oxnimbi, its oral sleep apnea pillApnimed, a Massachusetts biotech, filed with the SEC indicating it will seek an IPO of up to $160 million to finance the commercial launch of its oral obstructive sleep apnea therapy, Oxnimbi (AD10…